ERBB2 and breast carcinoma: These observations were further validated in fecal microbiome transplantation (FMT) experiments in HER2-positive breast cancer mouse models, where gut dysbiosis in NR mice impaired the recruitment of CD4+ T cells and granzyme B-positive cells.